CONTRADICTING EVIDENCE: rwPFS with single-agent IO was significantly shorter for all EGFR cases (2.4 m, 95% CI 2.1-2.8) compared to WT (3.3 m, 95% CI 3.1-3.6).

CONTRADICTING EVIDENCE:...KRAS patients could benefit from first-line immunotherapy (10.1 months, P < 0.05), patients with EGFR mutations have poor first-line immunotherapy outcomes, with a median PFS of only 3.0 months (P < 0.01)…

CONTRADICTING EVIDENCE: We assessed the association of clinical or molecular factors with the efficacy of ICI given either alone (ICI alone) or combined with other treatments (ICI-based combination treatments)….ICI had significantly lower efficacy in EGFR-mutated NSCLC while KRAS-mutated NSCLC showed higher efficacy.

Twenty-two NSCLC patients with EGFR mutations after TKI resistance were included from two hospitals....According to treatment strategies, the median PFS was 2.4 months (range 2.0-5.3 months) in the ICI monotherapy group and 5.9 months (range 2.8-9.0 months) in the ICI combined Chemotherapy group….ICI combined chemotherapy showed the best survival outcome among these groups, as demonstrated by the 12-month survival rate and PFS....The addition of ICIs plus chemotherapy may significantly improve progression-free survival among patients with locally advanced or metastatic non-squamous NSCLC who EGFR-TKIs resistance.

The PFS and OS of EGFR mutant patients were 3.9 (1.8-6.1) months and 18.0 (12.1-23.8) months, respectively. They tended to receive ICIs after resistance to EGFR-tyrosine kinase inhibitors (TKIs), and the proportion of second-, third-, fourth or further-line drugs was 38.1% (16/42), 11.9% (5/42), and 47.6% (20/42), respectively...EGFR mutant NSCLC patients tend to receive ICIs at the back line, and obtain reasonable survival benefits.

The overall response rate (ORR) was 8.0%, and the disease control rate (DCR) was 78.7%. The median PFS for all patients was 3.9 months (95% CI, 2.7-5.0), while the median OS was 9.9 months (95% CI, 5.3-14.6). We found that patients with longer response duration to EGFR-TKIs (≥10 months) showed a longer PFS when treated with immunotherapy compared with patients with shorter PFS-TKI (<10 months)....We found that combination regimen of immunotherapy plus chemotherapy plus antiangiogenetic agents may yield longer survival in patients with EGFR mutated NSCLC.

Most of the patients (21/24) received induction immunotherapy plus chemotherapy...For EGFR mutations, MPR rate was 33.3% (3/9) and pCR rate was 22.2% (2/9)

...263 consecutive pts with advanced NSCLC treated with ICI...Median OS for all pts was 20.8 months (m, CI95% 17.8–25.3) and median PFS was 4.8 m (CI95% 3.7–6.4) for ICI treatment…Median PFS was 1.8 m for EGFR mut pts and 6.1 m for EGFR wild type (p = 0.02).

The study included patients with EGFR and ALK-mutated NSCLC... In adjusted analyses for OS, the only statistically significant finding was for CIO vs. C (HR 0.55, 95% CI 0.31-0.98, p=0.04) among patients with EGFR-mutated tumors

CONTRADICTING EVIDENCE: STK11 mutation (Log-rank test, q=0.1), EGFR mutation (q<1e-3), and CN loss of PD-L1, PD-L2, and/or JAK2 (q=0.02) were all significantly associated with worse PFS after ICB. EGFR mutation was significantly associated with worse OS after ICB (q=0.19).

818 lung SpM were diagnosed over the course or at the time of diagnosis of 210 consecutive patients with NSCLC….In univariate analysis, good World Health Organisation (WHO) status (p < 0.0001), ambulatory status (Frankel score) (p < 0.0001), the absence of spine epiduritis (p < 0.0001), immunotherapy after SpM diagnosis (p < 0.0001), ALK gene rearrangement (p < 0.0001) and EGFR mutation (p < 0.0001) were associated with longer survival...